Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines
Drugs that inhibit dipeptidyl peptidase-4 (DPP-4) are conventionally regarded as incretin-based agents that signal through the glucagon-like peptide-1 (GLP-1) receptor. However, inhibition of DPP-4 also potent...
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Milton Packer Tags: Review Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Incretin Therapy | Stem Cell Therapy | Stem Cells